CSII - Cardiovascular Systems, Inc.
| Previous Close | 44.59 |
| Open | 44.56 |
| Bid | 45.61 x 900 |
| Ask | 45.63 x 1000 |
| Day's Range | 44.22 - 45.97 |
| 52 Week Range | 24.84 - 46.52 |
| Volume | 92,704 |
| Avg. Volume | 283,669 |
| Market Cap | 1.601B |
| Beta (3Y Monthly) | 1.28 |
| PE Ratio (TTM) | 778.95 |
| EPS (TTM) | 0.06 |
| Earnings Date | Aug 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.75 |
- Business Wire•7 days ago
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 Fourth-Quarter Earnings Conference Call Tuesday, August 6
Live Webcast at 3:30 p.m. CT
- Zacks•22 days ago
Here's Why You Should Retain Cardinal Health (CAH) Stock
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
- Zacks•25 days ago
HealthEquity (HQY) Set to Acquire WageWorks for $2 Billion
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
- Zacks•27 days ago
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
- Zacks•29 days ago
Here's Why You Should Retain Allscripts (MDRX) Stock Now
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
- Zacks•last month
Here's Why You Should Invest in Cooper Companies Stock Now
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
- Zacks•last month
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
- Zacks•last month
Wall Street Foresees a Fed Rate Cut: Winners & Losers
Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.
- Zacks•last month
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
- Simply Wall St.•last month
If You Had Bought Cardiovascular Systems (NASDAQ:CSII) Stock Three Years Ago, You Could Pocket A 128% Gain Today
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Zacks•last month
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
- Zacks•last month
Medical Products Industry Outlook: Growth Prospects Radiant
Medical Products Industry Outlook: Growth Prospects Radiant
- Zacks•last month
Here's Why You Should Add Cardiovascular Systems (CSII) Stock
Cardiovascular Systems (CSII) gains on high investors' confidence, courtesy of consistent positive results.
- Zacks•last month
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
- Business Wire•last month
Cardiovascular Systems, Inc. Announces First Patient Enrolled in REACH PVI Clinical Study
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first patient was enrolled in the REACH PVI study. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.
- Zacks•last month
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
- Zacks•last month
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Business Wire•last month
Cardiovascular Systems, Inc. to Present at the Raymond James Life Sciences & MedTech Conference
On Tuesday, June 18, 2019, Cardiovascular Systems’ Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Life Sciences & MedTech Conference at 9:45 a.m.
- Zacks•last month
Here's Why You Should Retain HMS Holdings (HMSY) Stock
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
- Zacks•2 months ago
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks•2 months ago
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
- Zacks•2 months ago
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
- Zacks•2 months ago
Cardiovascular Systems (CSII) Up 6.4% Since Last Earnings Report: Can It Continue?
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•2 months ago
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
- Zacks•2 months ago
Here's Why You Should Consider Betting On CONMED Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.
